Bioasis Technologies Inc () () CEO Deborah Rathjen tells Proactive the Canada-based firm and Italy-based Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed lysosomal storage disorders (LSDs).
Rathjen says under the terms of the agreement, international research-focused healthcare firm Chiesi Group, the parent of Chiesi Global Rare Diseases, will pay Bioasis an upfront payment of US$3 million.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
